Episode 400: 408. CME Obesity and MASH episode artwork

EPISODE · Sep 27, 2025 · 1H 2M

Episode 400: 408. CME Obesity and MASH

from Questioning Medicine · host Questioning Medicine

GLP1 drugs work but they likely need lifestyle modificationsNo convincing evidence GLP1 cause thyroid cancer in humans BUT contraindication if family history existStopping therapy usually results in weight gainInsurance coverage for weight loss is limited and variable  Semaglutide for type 2 diabetes max dose is 2.0 mg weekly Semaglutide for weight loss has a goal dose of 2.4 mg weekly Diagnose steatotic liver disease with imaging and 1 metabolic risk factor (or biopsy) After diagnosis check FIB-4: Low risk, continue to monitor with FIB-4 every 2-3yrs  Intermediate risk, order VCTE and consider referral if >F1  High risk order a VCTE and referral (20% end with SLD) 2 FDA approved medications for liver fibrosis are not cheap, expect insurance push back

Episode metadata supplied by the publisher feed · Published Sep 27, 2025

Embed this episode

NOW PLAYING

Episode 400: 408. CME Obesity and MASH

0:00 1:02:42

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Questioning Medicine?

This episode is 1 hour and 2 minutes long.

When was this Questioning Medicine episode published?

This episode was published on September 27, 2025.

Can I download this Questioning Medicine episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!